The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that Novo Nordisk’s long-acting insulin, Tresiba (degludec), is approved for use in Europe.

This has meant that Tresiba has got off to a slower start than hoped in the US following approval in late 2015, where it must also compete against Sanofi’s next generation long-acting insulin ...

“Without insulin, I die.” Novo Nordisk manufactures insulin products like NovoLog, Tresiba, Fiasp and Novolin. Novo Nordisk will also provide free insulin to qualifying patients below a ...

The QWINT-3 study compared efsitora with daily shots of Novo Nordisk’s NVO Tresiba (insulin degludec) for 78 weeks in T2D patients who have switched from daily basal insulin injections.

and now next-generation insulin analogs (Tresiba, Fiasp), which offer improved efficacy, safety, and convenience for patients. Tresiba also appears to offer greater dosing flexibility and less ...